Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Orexigen 1Q Loss Narrows

By R&D Editors | May 9, 2011

LA JOLLA, Calif. (AP) – Orexigen Therapeutics Inc. reported a narrower first-quarter loss and said it is preparing to discuss its experimental obesity drug Contrave with U.S. regulators.

The company said it lost $11.6 million, or 24 cents per share, down from $14.1 million, or 30 cents per share. Its revenue rose to $1.8 million from $22,000.

Analysts expected a loss of 20 cents per share and $900,000 in revenue, according to FactSet.

Orexigen said it will meet with the Food and Drug Administration later in the second quarter to discuss a proposal for Contrave. Orexigen said that together with partner Takeda Pharmaceuticals, it has submitted a plan to deal with the drug’s potential heart risks, which derailed its approval last year.

In the first quarter the company reported $857,000 from collaborations and $971,000 in license revenue. A year ago it had $22,000 in license revenue.

Orexigen said its research and development costs decreased to $6.6 million from $8 million. It filed for approval of Contrave in March 2010.

An FDA advisory panel voted in favor of approving the drug in December, but the agency said in February that it would not approve the drug. It asked Orexigen to run another study on the potential side effects on patients’ hearts.

Contrave combines bupropion and naltrexone. Bupropion is used to treat depression and help people quit smoking, while naltrexone is used to decrease cravings for alcohol and illegal drugs.

Date: May 9, 2011
Source: Associated Press

 

Related Articles Read More >

Certara’s COVID vaccine model is focus of Episode 8 of R&D 100 – The Podcast
New dangers in the woods — and the hope that research offers us
PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars